Pharmaceutical treatment for patients with mild asthma can minimize health care costs over time if patients use their prescribed medications and maintain control of their disease. We evaluated asthma-related health resource utilization for non-controller-naεve patients with mild, persistent asthma who received prescriptions for mometasone furoate (MF) administered via a dry powder inhaler or beclomethasone dipropionate (BDP) administered via a metered dose inhaler with a hydrofluoroalkane propellant.
Retrospective claims analyses were performed using an administrative claims database. We identified claims with the first date of a MF or BDP prescription (index date), examined these claims between January 1, 2005 and June 30, 2008, and selected patients (aged 12–65 y) who were enrolled in their health plan for ≥ 1 year before and ≥ 1 year after their index date. Patient demographics, comorbidities, and asthma resource utilization were measured for 365-day pre- and postindex periods. Postindex claims were analyzed for adherence to index drugs (MF or BDP), measured as the percentage of days covered and fill persistency, exacerbations, and receipt of short-acting β2-agonists (SABA). The cohorts were matched 1:1 according to their preindex demographics and comorbidities. Cohorts were compared using bivariate analysis for the preindex and postindex periods. The relationship between outcome variables and treatment cohorts were also explored using generalized linear regression modeling (GLM).
Among matched cohorts (n = 1273 per cohort), patients generally had similar preindex demographic characteristics and comorbidity prevalence rates. In both the bivariate and GLM analyses, MF patients had significantly better adherence (P < 0.0001) and significantly fewer SABA claims (P < 0.0001) when compared with BDP patients. A significantly lower rate of exacerbations was also seen for MF patients compared with BDP patients in the GLM analysis (P = 0.0002).
Patients with mild persistent asthma with prior medication use who received once-daily MF had better adherence, fewer exacerbations, and fewer SABA claims than patients who received twice-daily BDP.
Once-daily MF provides better asthma control than twice-daily BDP.
Prakash Navaratnam, Employee Schering-Plough Corporation; Consultant fee, speaker bureau, advisory committee, etc. Schering-Plough Corporation; No Product/Research Disclosure Information